Personalized Therapy  in Relapsed or Refractory CLL Personalized Therapy  in Relapsed or Refractory CLL

Personalized Therapy in Relapsed or Refractory CLL - PowerPoint Presentation

kittie-lecroy . @kittie-lecroy
Uploaded On 2018-02-23

Personalized Therapy in Relapsed or Refractory CLL - PPT Presentation

IWCLL Criteria for Treating CLL Other Considerations at Relapse Risk Factors at Relapse IGHV Status Affects Clinical Course Case 1 65YearOld Man Assessing This Patients Options TP53 Mutationdel17p and CIT ID: 634398

abbreviations 17p considerations del 17p abbreviations del considerations safety case agents year venetoclax cll therapy cont sequencing man efficacy




Download Presentation from below link

Download Presentation The PPT/PDF document "Personalized Therapy in Relapsed or Ref..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Presentation Transcript


Personalized Therapy in Relapsed or Refractory CLLSlide2

IWCLL Criteria for Treating CLLSlide5

Other Considerations at RelapseSlide6

Risk Factors at RelapseSlide7


Status Affects Clinical CourseSlide8

Case 1: 65-Year-Old ManSlide9

Assessing This Patient's OptionsSlide10

TP53 Mutation/del(17p) and CITSlide11

Monoclonal Antibodies and del(17p)Slide12

Efficacy of Ibrutinib in del(17p)Slide13

Safety of Ibrutinib Slide14

Additional Considerations for Novel AgentsSlide15

Overall Findings From RESONATE Slide16

Efficacy of Venetoclax in del(17p)Slide17

Safety of Venetoclax in Phase 2 TrialSlide18

TLS With VenetoclaxSlide19

PI3K-δ Inhibitor IdelalisibSlide20

Case 2: 43-Year-Old ManSlide21

Considerations for Sequencing TherapySlide22

Investigational Agents for Refractory CLLSlide23

Additional Considerations for Sequencing TherapySlide24

Minimal Residual DiseaseSlide25

Case 3: 77-Year-Old W


Assessing This Patient's OptionsSlide27

Prolonged LymphocytosisSlide28

Summary of Safety Concerns With Novel AgentsSlide29

Concluding RemarksSlide30


Abbreviations (cont)Slide32

Abbreviations (cont)Slide33

Abbreviations (cont)